article thumbnail

BioNTech plots first wave of cancer launches in 2026 as COVID vaccine sales continue to disappoint

Fierce Pharma

As BioNTech continues to endure a sharp decline in COVID-19 vaccine sales, the German mRNA specialist is looking ahead to the next leg of its commercial journey. With plans to have at least 10 potentially registrational trials underway by the end of 2024, BioNTech is plotting the first wave of its market debut in oncology from 2026 onward.

Sales 304
article thumbnail

Nektar pads wallet with $90M manufacturing plant sale to Ampersand

Fierce Pharma

The deal is expected to extend Nektar's cash runway into 2026 and help the company hone its development of novel immunology drugs.

article thumbnail

GSK dials up HIV sales projection to £7B by 2026, updates next-gen launch timelines

Fierce Pharma

Riding on the growth of long-acting antiretroviral therapy Cabenuva, GSK is laying out a more optimistic vision for its overall HIV business. Riding on the growth of long-acting antiretroviral therapy Cabenuva, GSK is laying out a more optimistic vision for its overall HIV business.

Sales 212
article thumbnail

Dr. Reddy's banned from China's drug procurement program after inspectors turn up manufacturing problems

Fierce Pharma

Reddy’s formulations production plant, China’s National Medical Products Administration has suspended the import, sale and use of the Indian drugmaker’s atomoxetine hydrochloride capsules for ADHD. 28, 2026. In addition, Dr. Reddy’s is prohibited from taking part in China’s drug procurement scheme through Feb.

article thumbnail

As Imbruvica loses steam, AbbVie takes $2.1B charge and points to CMS price negotiations

Fierce Pharma

Sales of AbbVie and Johnson & Johnson’s leukemia blockbuster Imbruvica are taking a hit from the introduction of BeiGene’s transformative oral treatment Brukinsa. Sales of AbbVie and Johnson & Johnson’s leukemia blockbuster Imbruvica are taking a hit from BeiGene’s Brukinsa.

Sales 224
article thumbnail

Despite Leqembi's launch pains, Eisai projects Alzheimer's med will reach $8.8B in the long run

Fierce Pharma

By Eisai’s 2026 fiscal year—which ends in March 2027—the company figures its Alzheimer's disease drug Leqembi can bring home 290 billion Japanese yen (nearly $2 billion) in global revenues. Come fiscal year 2032, those sales could potentially swell to a whopping 1.3 trillion yen ($8.8 billion).

Sales 198
article thumbnail

As pharma dives deeper into digital, ad fraud is getting worse

World of DTC Marketing

Online Ad Stats : Social media advertising budgets are expected to grow 11.76% annually by 2026. Buying programmatic ads can be an excellent way to quickly grow your company’s contacts list and create new sales opportunities. Not a single brand noticed this, and not a single media buyer noticed the fraud.

Pharma 208